This inventor holds 26 USPTO granted patents and 6 published patent applications, plus 9 CIPO patents and 13 EPO patents, primarily in Antibody Engineering. Top assignees: Ucbbiopharma Srl, Ucb Biopharma Sprl, Ucb Pharma, S.a.. Active years: 2011-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- High Wycombe, GB (2011)
- Berkshire, GB (2019 - 2022)
- Slough, GB (2013 - 2023)
Company Filing History:
11 out of 130 
10 out of 139 
4 out of 180 
Years Active: 2011-2026
Areas of Expertise:
Title: **Sam Philip Heywood: Innovation in Antibody Technologies**
Introduction
Sam Philip Heywood, an accomplished inventor located in Slough, GB, has made significant contributions to the field of biotechnology, specifically in antibody production. With an impressive portfolio of 23 patents, his work exemplifies the dedication to innovation and excellence in research and development.
Latest Patents
Some of Heywood's latest patents include groundbreaking methods designed to enhance the efficacy of recombinantly expressed antibody molecules. The first patent, titled “Method for increasing the percentage of monomeric antibody Fab-dsFv multimeric species,” details a process that increases the percentage of monomers in a composition of antibody molecules. This process involves a thermal conversion step that takes place at temperatures between 30 to 60°C while utilizing a reducing agent.
The second patent, “Method of monomerisation of recombinant antibody molecules,” also focuses on improving the monomer percentage in antibody compositions. It involves the treatment of the antibody composition with a denaturant, such as urea or Guanidine hydrochloride, again in the presence of a reducing agent. These innovative methods hold the potential for significant advancements in therapeutic antibody development.
Career Highlights
Throughout his career, Heywood has worked with reputable organizations, including UCB Biopharma Sprl and UCB Biopharma SRL. His experience at these institutions has enabled him to refine his expertise in the field and contribute to cutting-edge research in antibody technology.
Collaborations
In his journey through the industry, Heywood has collaborated with notable figures such as David Paul Humphreys and Emma Dave. These partnerships have likely played a pivotal role in the development and validation of his patents, further enriching the field of biotechnology.
Conclusion
Sam Philip Heywood stands out as a significant innovator within the biotechnology sector, exemplified by his extensive patent portfolio and collaborative efforts. His contributions to improving the production and efficacy of antibody molecules will undoubtedly have a lasting impact on biopharmaceutical research and development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile